The deal includes the exchange of clinical data and royalty on sales in China. Wide Line will also invest $1m in Thubrikar.
In 2014, Thubrikar signed its first license agreement with Brazil’s Labcor Laboratórios for sales across the South America.
The licensees sponsored clinical trials are expected to begin in Brazil and China in this year and next year.
Thubrikar developed and patented a low-profile, bovine pericardial, self-expanding valve called Optimum TAV to treat aortic stenosis.
Designed to mimic the natural aortic valve, the Optimum TAV can also be used as valve-in-valve and in bicuspid patients.
According to Thubrikar, the Optimum TAV has exceeded 890 million cycles in a durability test
Thubrikar Aortic Valve founder and president Dr Mano Thubrikar said: “We are very pleased to expand our global partnerships for the Optimum TAVI System, to raise additional funds, and to have Tony join our board.
“We look forward to Labcor’s First-In-Human studies this Fall and royalties from both licensees after their regulatory approvals.”
In addition, the firm designed a delivery catheter for transfemoral, transapical, and other access routes.
